207 related articles for article (PubMed ID: 31357193)
21. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Ye Z; Wang Y; Wu H; Song T; Li X; Liu Q; Wang C
Chembiochem; 2021 Jan; 22(1):129-133. PubMed ID: 32979005
[TBL] [Abstract][Full Text] [Related]
22. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
Abdel-Rahman O; Fouad M
Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
[TBL] [Abstract][Full Text] [Related]
23. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Rhodes JM; LoRe VA; Mato AR; Chong EA; Barrientos JC; Gerson JN; Barta SK; Landsburg DJ; Nasta SD; Svoboda J; Loren AW; Schuster SJ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):438-444.e1. PubMed ID: 32197990
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Graf SA; Cassaday RD; Morris K; Voutsinas JM; Wu QV; Behnia S; Lynch RC; Krakow E; Rasmussen H; Chauncey TR; Kanan S; Soma L; Smith SD; Gopal AK
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):176-181. PubMed ID: 33358575
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
Merola E; Dal Buono A; Denecke T; Arsenic R; Pape UF; Jann H; Wiedenmann B; Pavel ME
Pancreas; 2020 Aug; 49(7):912-917. PubMed ID: 32658073
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.
Szklener K; Michalski A; Żak K; Piwoński M; Mańdziuk S
Cells; 2022 Apr; 11(8):. PubMed ID: 35456016
[TBL] [Abstract][Full Text] [Related]
28. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
[TBL] [Abstract][Full Text] [Related]
29. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Fancher KM; Pappacena JJ
Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
[TBL] [Abstract][Full Text] [Related]
30. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
31. Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Steele L; George C; Cerio R; O'Toole EA
Clin Exp Dermatol; 2022 Feb; 47(2):488-490. PubMed ID: 34882824
[No Abstract] [Full Text] [Related]
32. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
[TBL] [Abstract][Full Text] [Related]
33. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
[TBL] [Abstract][Full Text] [Related]
35. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
Shulman K; Kazarin O; Tannous E; Sofer O
Isr Med Assoc J; 2021 Jun; 23(6):385-386. PubMed ID: 34155856
[No Abstract] [Full Text] [Related]
37. Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
Visentin A; Imbergamo S; Trimarco V; Pravato S; Romano Gargarella L; Frezzato F; Scapinello G; Bertorelle R; Piva E; Facco M; Semenzato G; Piazza F; Trentin L
Hematol Oncol; 2020 Dec; 38(5):823-826. PubMed ID: 32979282
[TBL] [Abstract][Full Text] [Related]
38. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
[TBL] [Abstract][Full Text] [Related]
40. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
